Explore the strategic collaboration between Shilpa Medicare and Orion Corporation to launch a nivolumab biosimilar, enhancing access to cancer treatments in Europe.

Explore the proposed federal regulation for 2029 affecting Medicare pricing strategies for drugs. Understand the implications and upcoming changes in healthcare policy.

Explore the key impact of generic drugs and biosimilars on reducing prescription costs in the U.S. healthcare system, including legislative efforts and market dynamics.

Explore how BCBS Michigan saved $147 million by transitioning to biosimilars, enhancing patient access while reducing healthcare costs. Learn more!